China NMPA approves CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy for thalassemia
EdiGene, Inc announced the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved the Company’s Investigational New Drug (IND) application for ET-01, an investigational CRISPR/Cas 9 gene-editing therapy for patients with transfusion dependent β-thalassemia. It marks the first gene-editing therapy and the first hematopoietic stem cell therapy IND application approval in China.